VAPO - Vapotherm, Inc.

NYSE - NYSE Delayed Price. Currency in USD
14.00
+0.03 (+0.21%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close14.35
Open14.13
Bid14.08 x 1400
Ask14.05 x 900
Day's Range13.77 - 14.52
52 Week Range13.00 - 24.63
Volume223,265
Avg. Volume112,310
Market Cap244.992M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-4.38
Earnings DateOct 26, 2019 - Oct 31, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.33
Trade prices are not sourced from all markets
  • What Percentage Of Vapotherm, Inc. (NYSE:VAPO) Shares Do Insiders Own?
    Simply Wall St.

    What Percentage Of Vapotherm, Inc. (NYSE:VAPO) Shares Do Insiders Own?

    The big shareholder groups in Vapotherm, Inc. (NYSE:VAPO) have power over the company. Large companies usually have...

  • Business Wire

    Vapotherm Announces Pricing of Public Offering of Common Stock

    Vapotherm, Inc. (VAPO) (“Vapotherm”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced today the pricing of its public offering of 3,105,000 shares of its common stock at a price to the public of $14.50 per share. All of the shares will be offered by Vapotherm. In addition, Vapotherm has granted the underwriters a 30-day option to purchase up to an additional 465,750 shares of its common stock at the public offering price less underwriting discounts and commissions.

  • Business Wire

    Vapotherm Announces Proposed Public Offering of Common Stock

    Vapotherm, Inc. (VAPO) (“Vapotherm”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced today the commencement of a proposed public offering of 2,600,000 shares of its common stock. All of the shares will be offered by Vapotherm. Vapotherm also expects to grant the underwriters a 30-day option to purchase up to an additional 390,000 shares of common stock.

  • Vapotherm, Inc. (VAPO) Q2 2019 Earnings Call Transcript
    Motley Fool

    Vapotherm, Inc. (VAPO) Q2 2019 Earnings Call Transcript

    VAPO Vapotherm, Inc. (VAPO) Q2 2019 Earnings Call Transcript

  • Business Wire

    Vapotherm Reports Second Quarter 2019 Financial Results

    Vapotherm, Inc. , a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced its financial and operating results for the second quarter ended June 30, 2019.

  • ACCESSWIRE

    Vapotherm, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / July 29, 2019 / Vapotherm, Inc. (NYSE: VAPO ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on July 29, 2019 at 4:30 PM Eastern ...

  • Business Wire

    Vapotherm to Report Second Quarter 2019 Financial Results

    Vapotherm, Inc. (VAPO) (“Vapotherm”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced today that it will release financial results for the second quarter of 2019 after the close of trading on Monday, July 29, 2019. Vapotherm’s management team will host a corresponding conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments.

  • Business Wire

    Vapotherm to Present at the William Blair 39th Annual Growth Stock Conference

    Vapotherm, Inc. (VAPO), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be presenting at the William Blair 39th Annual Growth Stock Conference on Wednesday, June 5th at the Loews Chicago Hotel in Chicago, Illinois. Vapotherm is scheduled to present at 3:20pm Central Time. A webcast replay of the presentation will be available for 90 days following the presentation in the Event Archive section of Vapotherm’s Investor website at http://investors.vapotherm.com/.

  • Vapotherm Inc (VAPO) Q1 2019 Earnings Call Transcript
    Motley Fool

    Vapotherm Inc (VAPO) Q1 2019 Earnings Call Transcript

    VAPO earnings call for the period ending March 31, 2019.

  • Business Wire

    Vapotherm to Present at the Bank of America Merrill Lynch 2019 Health Care Conference

    Vapotherm, Inc. (VAPO), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be presenting at the Bank of America Merrill Lynch 2019 Health Care Conference on Wednesday, May 15 at the Encore Hotel in Las Vegas, Nevada. Vapotherm is scheduled to present at 5:15pm Pacific Time. A webcast replay of the presentation will be available for 90 days following the presentation in the Event Archive section of Vapotherm’s Investor website at http://investors.vapotherm.com/.

  • Associated Press

    Vapotherm: 1Q Earnings Snapshot

    On a per-share basis, the Exeter, New Hampshire-based company said it had a loss of 76 cents. The medical technology company posted revenue of $12.3 million in the period. For the current quarter ending ...

  • Business Wire

    Vapotherm Reports First Quarter 2019 Financial Results

    Vapotherm, Inc. , a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced its financial and operating results for the first quarter ended March 31, 2019.

  • You Might Like Vapotherm, Inc. (NYSE:VAPO) But Do You Like Its Debt?
    Simply Wall St.

    You Might Like Vapotherm, Inc. (NYSE:VAPO) But Do You Like Its Debt?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Investors are always looking for growth in small-cap stocks like Vapotherm, Inc. (NYSE:VAPO), with a...

  • Business Wire

    Vapotherm to Report First Quarter 2019 Financial Results

    Vapotherm, Inc. (VAPO) (“Vapotherm”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced today that it will release financial results for the first quarter of 2019 after the close of trading on Tuesday, May 7, 2019. Vapotherm’s management team will host a corresponding conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments. To listen to a live webcast, please visit the Investors section of the Vapotherm’s website at: http://investors.vapotherm.com/events-and-presentations/events.

  • Business Wire

    Emergency Department Subgroup Study Showed Hi-VNI® Technology Had Similar Outcomes to Non-invasive Positive Pressure Ventilation in Management of Respiratory Distress Among Acute Decompensated Heart Failure Patients

    Vapotherm, Inc. (VAPO), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology, today announced that a paper published in the American Journal of Emergency Medicine, titled “HVNI vs NIPPV in the treatment of Acute Decompensated Heart Failure: subgroup analysis of a multi-center trial in the ED” showed equivalent outcomes between Hi-VNI Technology and Non-invasive Positive Pressure Ventilation (NiPPV) in the treatment of respiratory distress in a subgroup of patients suffering from acute decompensated heart failure (ADHF). “These results represent another proof point that Vapotherm Hi-VNI Technology is a viable alternative to relieve undifferentiated respiratory distress across a wide variety of patient populations,” said Joe Army, President and CEO.

  • GuruFocus.com

    Vapotherm Inc (VAPO) Files 10-K for the Fiscal Year Ended on December 31, 2018

    For the last quarter Vapotherm Inc reported a revenue of $42.4 million, compared with the revenue of $30.12 million during the same period a year ago. Warning! GuruFocus has detected 1 Warning Sign with VAPO.

  • Associated Press

    Vapotherm: 4Q Earnings Snapshot

    The Exeter, New Hampshire-based company said it had a loss of $1.39 per share. Losses, adjusted to extinguish debt, came to $1.28 per share. The medical technology company posted revenue of $11.7 million ...

  • Business Wire

    Vapotherm Reports Fourth Quarter and Fiscal Year 2018 Financial Results

    2018 Revenue of $42.4 Million Reflects 19.0% Increase Over Prior Year

  • Business Wire

    Vapotherm® Releases Next Generation of Capital Unit: Precision Flow Hi-VNI™ System

    Vapotherm, Inc. (VAPO), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced the release of the next generation of its capital unit: the Precision Flow Hi-VNI system. For this generation of the Precision Flow® system, both the hardware and software have been updated to improve reliability, and to comply with the EMC 4th Edition requirements for medical devices, IEC 60601-1-2:2014. As with all the other models of the Precision Flow system, this generation provides Hi-VNI Technology, the innovation that delivers Mask-Free NIV™ for spontaneously breathing patients.

  • Business Wire

    Vapotherm to be Added to the Russell 2000®, 3000® and Microcap® Indexes

    Vapotherm, Inc. (VAPO) announced today that it has been added to the Russell 2000®, Russell 3000® and Russell Microcap® Indexes, effective after market close on December 21, 2018, as part of Russell’s quarterly addition of companies with recent initial public offerings. The Russell 2000 Index measures the performance of the small-cap segment of the U.S. equity market and is a subset of the Russell 3000 Index. Membership in the Russell 2000 Index includes automatic inclusion in the appropriate growth and style indexes, such as the Russell Microcap Index, which represents small-cap and micro-cap stocks.

  • Business Wire

    Clinical Study Shows Vapotherm’s New IntellO2™ Module for Precision Flow® System Significantly Improves Maintenance of Premature Neonates in Target Oxygenation Range

    Vapotherm, Inc. today announced the publication of a key prospective, multi-center, controlled, order-randomized crossover trial. The study demonstrates that using the IntellO2 automated oxygen controller module helped clinicians maintain neonates in the physician-prescribed oxygen saturation range significantly better than manual control alone. The results were published by Reynolds and colleagues in the Archives of Disease in Childhood: Fetal and Neonatal Edition, entitled “Randomised crossover study of automated oxygen control for preterm infants receiving nasal High Flow.” The data show that trained staff were able to keep the babies’ oxygen saturation in the target range 49% of the time with manual controls alone.

  • Business Wire

    Vapotherm Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    Vapotherm, Inc. (VAPO) (“Vapotherm”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced the closing of its initial public offering of 4,600,000 shares of common stock, at a price to the public of $14.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to an additional 600,000 shares of common stock. All of the shares of common stock were offered by Vapotherm.